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Abstract
The lysosomal degradation pathway of macroautophagy (herein referred to as autophagy) plays a crucial role in
cellular physiology by regulating the removal of unwanted cargoes such as protein aggregates and damaged
organelles. Over the last five decades, significant progress has been made in understanding the molecular
mechanisms that regulate autophagy and its roles in human physiology and diseases. These advances, together with
discoveries in human genetics linking autophagy-related gene mutations to specific diseases, provide a better
understanding of the mechanisms by which autophagy-dependent pathways can be potentially targeted for treating
human diseases. Here, we review mutations that have been identified in genes involved in autophagy and their
associations with neurodegenerative diseases.
Introduction
The original definition of autophagy (Greek, “self-eating”)
is the delivery of cytoplasmic cargoes to the lysosome for
degradation. This process is conserved in all eukaryotic
organisms, occurs at basal levels in nearly all cell types, and
is tightly regulated by diverse intracellular and extracellular
cues. Autophagy is mediated by autophagy-related genes
required for the efficient formation and maturation of
autophagosomes (double-membraned structures) that are
targeted for degradation and recycling after fusion with
lysosomes.
The first morphologically recognizable autophagic
structures in mammalian cells are cup-shaped double
membraned structures called phagophores. After the
edges of the phagophores extend and fuse, they become
autophagosomes. At the initial steps of autophagy, the
ULK1 kinase complex (comprising of ULK1, FIP200,
ATG13, and ATG101) plays a major role by phosphor-
ylating multiple downstream effectors1. Two distinct
Beclin 1/class III phosphatidylinositol 3-kinase (PI3KC3)
complexes generate phosphatidylinositol 3-phosphate
(PI3P) to act in autophagosome nucleation (Complex 1:
Beclin 1, VPS34, VPS15, and ATG14), or endolysosomal
and autophagolysosomal maturation (Complex 2: Beclin
1, VPS34, VPS15, and UVRAG). WIPI (WD repeat
domain phosphoinositide-interacting) proteins together
with ATG2, function in the early stages of membrane
elongation at the site of PI3P generation. Autophagosome
membrane expansion and completion involves the for-
mation of the ATG5-ATG12-ATG16L1 complex and
LC3/GABARAP family protein lipidation. The core ATG
proteins are necessary, but not sufficient for degradative
autophagy (Fig. 1). Autophagosomal degradation cannot
proceed without successful fusion to functional lyso-
somes. Research in the past decade has unmasked several
key factors required for autophagolysosomal fusion, such
as the GABARAP subfamily, as well as the
CORVET–HOPS and the STX17–SNAP29–VAMP8/
VAMP7 SNARE complexes2–5.
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Autophagy was initially considered as a bulk degrada-
tion process, which lacks substrate specificity. However,
we now know that there can be specificity in controlling
the choice of substrate that will be degraded by autop-
hagosomes. Numerous studies have reported processes
enabling the preferential degradation of aggregation-
prone misfolded proteins, such as those involved in the
pathogenesis of neurodegenerative diseases, and various
organelles, such as damaged mitochondria (Fig. 2)6–9.
Substrates either contain an LC3-interacting region (LIR)
motif that directly binds LC3 or they are labeled with
ubiquitin, which is recognized by receptor proteins (also
called autophagy adaptors). Receptor proteins contain
both an ubiquitin-binding domain and a LIR motif, thus
serving as a bridge between the substrates and the LC3
conjugated to phagophores (Fig. 2). Some autophagy
adaptors/receptors, such as the autophagy-linked FYVE
protein (ALFY) and optineurin, have a dual role as they
can bind cargoes, but they also regulate the recruitment of
the ULK1 and PI3KC3 complexes to initiate autophago-
some formation10–13.
Autophagy is required for normal maintenance and
function of the mammalian nervous system14,15. Multiple
studies employing tissue-specific knockout mouse models
of core autophagy genes have revealed that autophagy
plays a key role in clearing aggregate-prone proteins
associated with neurodegeneration and its impairment
results in reduces survival and causes progressive
Fig. 1 Autophagy overview. The ULK1 complex activates the PI3KC3 complexes, resulting in PI3P synthesis and the nucleation of pre-
autophagosome structures that may receive membrane from multiple sources, such as the ER, Golgi, plasma membrane, and recycling endosomes.
PI3P is the recruitment signal for WIPI proteins and the ATG12–ATG5–ATG16L1 complex, both are required for autophagosome membrane
expansion and completion. Subsequent fusion to lysosomes results in degradation of autophagosomal contents.
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neurodegeneration across broad areas of the central and
peripheral nervous system14,15. Here, we review the
known genetic mutations of molecules involved in bulk
and selective autophagy and their associations with neu-
rodegenerative diseases (summarized in Table 1).
Autophagy related 5 (ATG5)
ATG5 is a core autophagy protein that functions in
autophagosome formation and is required for both of the
ubiquitin-like conjugation systems involved in LC3 lipi-
dation. ATG5 is first irreversibly conjugated to ATG12 by
the E1-like ATG7 and E2-like ATG1016. Then, the
ATG5–ATG12 conjugate non-covalently interacts with
ATG16L1 to form the ATG5–ATG12–ATG16L1 com-
plex, which functions as an E3-like enzyme for the cova-
lent conjugation of the C-terminal glycine of LC3 to
phosphatidylethanolamine (PE), resulting to LC3-II for-
mation17 (Fig. 1).
Whole-exome sequencing of two Turkish siblings with
childhood ataxia associated with hypoplasia of the cere-
bellar vermis identified a homozygous missense mutation
(E122D) in ATG518. E122 is located in the vicinity of the
ATG12–ATG5 interaction surface and the E122D muta-
tion impaired the conjugation of ATG5 to ATG12. In
patient‐derived lymphoblastoid cell lines, the levels of
ATG5–ATG12 conjugate is severely reduced, therefore
leading to impaired autophagosome formation18. Ataxia is
a common clinical sign of impaired coordination of
movement and balance during voluntary activity, mainly
caused by dysfunction of the complex circuitry connect-
ing the basal ganglia, cerebellum, and cerebral cortex.
Dysfunction of the cerebellar vermis causes staggering
Fig. 2 Autophagy receptors and selective autophagy. Through the action of autophagy receptors, specific cargoes are recognized and
incorporated into autophagosomes for selective degradation180. Autophagy receptors can therefore mediate aggrephagy, mitophagy, pexophagy,
ER-phagy, lysophagy, xenophagy, or pexophagy. While this figure aims to provide an overview of the many autophagy receptors involved in different
forms of selective autophagy, we have focussed in the text on the most important examples involved in Mendelian neurodegenerative diseases, like
P62, ALFY, and OPTN.
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gait, asynergic movements, dysmetria, nystagmus, inten-
tional tremor, and difficulty in forming speech19.
SNPs and variants causing dysregulation of ATG5
expression levels have also been reported. A homozygous
ATG5 variant (rs6568431 AA genotype) resulting in lower
ATG5 expression was identified to be associated with
childhood cerebral palsy (CP)20. It will be important to
validate these findings in subsequent replication studies.
CP is a group of permanent motor disorders, often
accompanied by disturbances of sensation, perception,
Table 1 Summary of genes involved in autophagy and neurodegeneration.
Gene Role in autophagy and disease Ref.
ATG5 Core ATG protein required for LC3 lipidation. Childhood ataxia- or cerebral palsy-associated mutations impair its
conjugation to ATG12 or its protein expression, resulting in autophagosome formation impairment.
16–18,20
VSP15 Core component of the PI3KC3 complex, required for PI3P biogenesis. The L1224R disease-linked mutation leads to
defects in PI3KC3 complex assembly and PI3P production.
23,26
WIP4 PI3P effector that mediates autophagosome formation. BPAN-associated mutations show defects in autophagy flux. 27,28,31,35
p62/
SQSTM1
Autophagy receptor. ALS/FTLD-linked mutations impair its binding to substrates or LC3. 36–39,41,42,
45,46,48
ALFY Autophagy receptor that is involved in autophagosome nucleation. MCPH-associated mutations lead to loss of ALFY’s
activity.
10,49,50,52,53
Parkin E3 ligase important for mitophagy. Early-onset PD-associated mutations mostly affect its E3 ligase activity 54,181
PINK1 Kinase that activates and recruits Parkin to damaged mitochondria. Most of the early onset PD-associated mutations
affect its kinase domain, resulting in loss of function.
59,60,67,181
OPTN Autophagy receptor also involved in autophagosome formation and maturation. The E50K glaucoma-associated
mutation
leads to increased interaction with TBK1, resulting in loss of proper oligomerization and solubility of OPTN. The
ALS-associated Q398X and E478G mutations cause a defect in autophagosome–lysosome fusion due to failure in
binding with myosin VI.
12,13,85,
87–90,100,
182
TBK1 Kinase that targets autophagy receptors and other molecules involved in autophagosome nucleation, maturation and
fusion to lysosomes. Most ALS-linked mutations result in loss of either a functional kinase or binding to its targets.
62,84,
102–105,
107,108
VPS13D Important for mitophagy. Disease-associated variants display changes in mitochondrial morphology and distribution. 111–113
PEX13 Involved in mitophagy and virophagy. ZS-associated mutations lead to reduced activity or levels of PEX13 result in
impaired peroxisome function and mitophagy.
116–118,120,
124,125
VCP Required for autophagosome maturation. IBMPFD- and ALS-linked mutations impair its chaperone activity or protein
expression.
128–134
UBQLN2 Binds LC3 and promotes autophagosomal degradation, also regulates lysosomal acidification. ALS-associated mutations
impair its ability to bind its partners and result in defects in protein degradation via the proteasome and autophagy.
135–140
Spastizin Regulates ALR, endosome trafficking and autophagosome–lysosomal fusion. SPG15-linked mutations lead to loss of a
functional protein, resulting in impaired autophagosome maturation and degradation.
145,146,148,
150–153
Spatacsin Regulates ALR and endosome trafficking. SPG11-associated mutations result to loss of function and defects in lysosomal
degradation.
146,148–150
TECPR2 LC3-binding protein, probably involved in autophagosome formation. SPG49-linked mutations result in protein loss or
instability.
154–156
EPG5 Tethering protein that regulates autophagosome–lysosomal fusion. Vici syndrome-associated mutations result in loss of
function, leading to autophagy impairment.
160–166
VSP11 Core CORVET–HOPS complex subunit that regulates autophagosome–lysosomal fusion. gLE-linked mutations result in
protein instability and defects in autophagosome degradation.
168–170
SNX14 Most likely required for lysosomal function. SCAR20-associated mutations lead to the loss of a functional protein, resulting in
lysosomal impairment and defective autophagosome degradation.
174,175,
177–179
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cognition, communication and behavior, epilepsy, and
secondary musculoskeletal problems. It is caused by
nonprogressive disturbances that occurred in the devel-
oping fetal or infant brain21. A heterozygous ATG5 var-
iant, located in the promoter region (106774459T > A),
which leads to increased expression levels of ATG5, was
identified in one Parkinson’s disease (PD) patient22.
However, it is unclear how and if this variant contributes
to the PD pathogenesis.
Vacuolar protein sorting-associated protein 15
(VPS15)
VPS15 is the regulatory subunit and membrane target-
ing factor of the PI3KC3 complex, which regulates the
production of PI3P23. VPS15 and VPS34 together with
beclin 1 form three distinctive PI3K complexes. These
core components together with ATG14L form the
PI3KC3 complex 1, which is essential for the induction of
canonical autophagy. In PI3KC3 complex 2, ATG14L is
replaced by UVRAG, and the activity is directed towards
regulation of endocytosis and endosome fusion, and in
complex 3 Rubicon binds to UVRAG to negatively reg-
ulate the activity of this complex24,25.
A VPS15 missense mutation (L1224R) has been iden-
tified in a patient that presented with severe cortical and
optic nerve atrophy, localized cortical dysplasia, intellec-
tual impairment, spasticity, ataxia, psychomotor delay,
muscle wasting, pseudobulbar palsy, a mild hearing defi-
cit, and late-onset epilepsy26. Human fibroblasts carrying
the L1224R mutation have an accumulation of autophagy
substrates, as well as reduced levels of VPS15, VPS34, and
beclin126, indicating that the PI3KC3 complex assembly
and therefore PI3P production is impaired.
WD repeat domain phosphoinositide-interacting
protein 4 (WIPI4)
WIPI proteins (WIPI1–WIPI4) are the only known
PtdIns3P-binding proteins with conserved PI3P effector
functions that recruit downstream regulators and facil-
itate the formation of autophagosomes27. WIPI4 associ-
ates with ATG2, a lipid-transfer protein that functions in
autophagosome expansion and closure28. The recruit-
ment of ATG2–WIPI4 complex onto phagophores
requires ATG9 and the TRAPPIII complex that is
required for autophagosome closure29.
Mutations of WIPI4 (encoded by the WDR45 gene),
resulting in truncated proteins that are prone to degra-
dation, were found to cause an X-linked dominant sub-
type of neurodegeneration with iron accumulation
(NBIA), known as BPAN (beta-propeller protein-
associated neurodegeneration)30–34. Central nervous sys-
tem (CNS)-specific Wdr45 knockout mice recapitulate
some phenotypes of BPAN and show ubiquitin-positive
protein aggregates and p62/SQSTM1 accumulation in
neurons, particularly in axons, suggesting a blockage of
autophagy flux35. Lymphoblastoid cell lines derived from
BPAN patients showed impaired autophagy flux and
accumulation of LC3-positive autophagosome mem-
branes that were also positive for ATG931. BPAN patients
are characterized by neurological movement disorder,
progressive degeneration of the nervous system, and
strong iron deposition in the substantia nigra (SN) and
globus pallidus (GP).
Sequestosome 1 (SQSTM1; also known as p62)
p62/SQSTM1 is a multifunctional scaffold protein,
which plays important roles as an adaptor/receptor for
selective autophagy, but it also mediates activation of the
mammalian target of rapamycin complex 1 (mTORC1) on
lysosomes and the Keap1–Nrf2 pathway, a major cellular
defense mechanism against oxidative stress36. Among its
multiple domains, Phox1 and Bem1p domain (PB1), LIR,
and the C-terminal ubiquitin associated domain (UBA)
domains are required for selective autophagy37–39,
whereas the Kelch-like ECH associated protein 1 (Keap1)-
interacting region is required for Keap1 binding40.
Several mutations in p62/SQSTM1 have been identified
in cases of familial and sporadic amyotrophic lateral
sclerosis (ALS) and frontotemporal lobar degeneration
(FTLD), leading to loss of function of p62/SQSTM1 in
selective autophagy41,42, or a decreased interaction with
Keap143. In the brains of the ALS–FTLD patients, p62/
SQSTM1 is detected in ubiquitin intracellular protein
aggregates, suggesting that p62/SQSTM1 and ubiquitin
contributes to the formation of inclusions44. The familial
ALS-associated P392L mutation45, located in the UBA
domain of p62/SQSTM1, impairs the binding ability of
p62/SQSTM1 to polyubiquitin chains, resulting in loss of
basal autophagy46. Moreover, the L341V mutation in the
LIR domain found in sporadic ALS47 impairs its binding
to LC3, therefore inhibiting p62/SQSTM1-mediated
delivery of ubiquitinated substrates to autophagosomes48.
Also, the ALS–FTLD-associated p62/SQSTM1 P348L and
G351A mutations impair Keap1 binding, resulting in
reduced Nrf2 signaling and aberrant expression of oxi-
dative response genes48. ALS and FTLD are highly related
neurodegenerative disorders on the same pathological
disease spectrum. ALS clinical signs include motor neu-
ron degeneration, resulting in progressive muscle weak-
ness and paralysis, eventually leading to fatal respiratory
failure. The term FTLD covers a range of clinical syn-
dromes associated by atrophy of the frontal temporal
lobes in the brain, characterized by behavioral and per-
sonality changes41
Autophagy-linked FYVE protein (ALFY)
ALFY (encoded by theWDFY3 gene) is a member of the
Beige and Chendiak-Higashi (BEACH) domain-
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containing protein family involved in vesicle transport,
membrane fission and fusion events, and autophagy49.
ALFY is required for the recruitment of ubiquitinated
proteins to cytosolic p62/SQSTM1 bodies and nuclear
promyelocytic leukemia nuclear bodies (PML-NBs)10.
ALFY, together with p62/SQSTM1 and interactions with
LC3 and the ATG5–ATG12 complex, drives the forma-
tion of larger aggregates that are targeted for autophagic
degradation10,11. In addition to its role as an autophagy
receptor, ALFY binds PI3P in the autophagic membrane
through its FYVE domain and facilitates the binding of
ATG5–ATG12 to ATG1610, therefore acting as an
autophagosome nucleation inducer.
WDFY3 is a recently identified disease gene where
mutations are seen in autosomal dominant primary
microcephaly (MCPH)50. Primary microcephaly is a group
of autosomal disorders characterized by a reduction in the
number of neurons, resulting in a smaller brain volume
coupled with a head circumference of at least three
standard deviations below the age- and sex-specific
means50,51. Individuals with MCPH usually have intel-
lectual disability and speech delay, with varying degrees of
motor delay50,51. The heterozygous mutation R2637W in
ALFY, located in the PH domain, is directly related to its
ability to remove protein aggregates from the cytosol and
flies expressing this mutation have smaller and malformed
brains with clusters of cells containing ALFY-positive
aggregates52. Lack of ALFY activity leads to aberrant
activation of the Wnt signaling pathway, resulting in
reduced neuronal differentiation and microcephaly52.
Similarly, another mutation located in the PH domain
(G2558S) was found to be associated with intellectual
disability and microcephaly53. By contrast, a missense
mutation in the BEACH domain (R2823W), as well as
several de novo pathogenic variants of WDFY3 leading to
haploinsufficiency of the gene, result in macrocephaly and
cause an autosomal dominant neurodevelopmental dis-
order with mild-to-moderate neurodevelopmental delay
and intellectual disability associated with deficits in motor
coordination, as well as autism spectrum disorders53.
Interestingly, studies on heterozygous Wdfy3+/lacZ mice
showed that Wnt signaling is inhibited53. The proposed
mechanism for this discrepancy describes that mutations
on the PH domain of ALFY would lead to aberrant
upregulation of Wnt signaling and microcephaly, whereas
truncating variants and mutations in the BEACH domain
will lead to downregulation of Wnt signaling and
macrocephaly53.
Parkin and PINK1
The E3 ligase Parkin and the serine–threonine kinase
PINK1 (encoded by the PARK2 and PARK6 genes,
respectively) play important roles in the maintenance of
mitochondrial quality and the degradation of damaged
mitochondria through mitophagy54,55. PINK1, located in
the inner mitochondrial membrane, is constitutively
cleaved in the inner mitochondrial membrane by the
presenilin-associated rhomboid-like protein and is
degraded by the proteasome56–58. However, when mito-
chondrial membrane potential is disrupted, PINK1 is no
longer imported into mitochondria and accumulates on
the outer mitochondrial membrane56,57. PINK1 on the
outer membrane phosphorylates Parkin as well as ubi-
quitin located on mitochondria, thereby releasing Parkin’s
autoinhibition and inducing its E3 ligase activity, as
well as promoting its recruitment to damaged mito-
chondria59–61. The assembly of Parkin-mediated poly-
ubiquitin chains on damaged mitochondria initiates the
recruitment of autophagy receptors, such as p62/
SQSTM1 and optineurin (OPTN), as well as activation of
the TANK-binding kinase1 (TBK1)37,62,63. PINK1, inde-
pendently of Parkin, also recruits OPTN and NDP52/
CALCOCO2 to mitochondria to activate mitophagy,
which also induce the recruitment of the components of
the autophagosome formation machinery, such as ULK1
and WIPI proteins64.
Parkin and PINK1 mutations are a major cause of early-
onset PD65–70. Considerations have been raised regarding
the roles of Parkin and PINK1 in mitophagy, as studies
using primary neurons or neurons derived from induced
pluripotent stem cells resulted in several controversies71–73.
However, studies, using patient derived fibroblasts have
revealed aberrant mitochondrial function and morphol-
ogy74–78, indicative of mitophagy dysfunction. Patients
with PARK2 mutations show the typical signs character-
izing PD, which are rigidity, bradykinesia, postural
instability, and tremor, as well as additional signs such as
freezing gait and lower foot dystonia. In contrast to typical
idiopathic PD, cognitive dysfunction, hallucination, and
REM behavioral disorder are not seen. Patients with
PARK6 mutations show clinical symptoms similar to
sporadic PD79. However, the accumulation of Lewy body
aggregates, a pathognomonic feature of sporadic PD, is
not a typical feature of Parkin-associated Parkinsonism80.
Optineurin (OPTN)
OPTN is a highly conserved and ubiquitously expressed
cytoplasmic protein that contains several domains
including a LIR motif and an ubiquitin-binding region81–83.
OPTN is an autophagy adaptor/receptor protein that
participates particularly in the selective autophagy of
protein aggregates/pathological inclusions, damaged
mitochondria, and intracellular pathogens12,62,84–87.
OPTN is recruited by PINK1 to damaged mitochondria
and subsequently recruits ULK1 in an ubiquitin-binding
dependent manner12. OPTN also promotes autophago-
somal elongation by mediating the recruitment of the
ATG12–ATG5–ATG16L1 complex to phagophores13.
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OPTN also regulates autophagosomal maturation
through its interaction with the GTPase Rab1a88, and
autophagosome–lysosome fusion through its interaction
with the myosin VI complex89,90.
Mutations and polymorphisms in OPTN have been
linked to neurodegenerative diseases, including ALS91–93
and glaucoma82,83,94. A number of studies have shown
that glaucoma-associated OPTN mutations induce
defective autophagy and increased cell death both in vitro
as well as in vivo (in mice expressing the glaucoma-linked
E50K mutation)95–98. In ALS, OPTN mutations have
pathogenic effects as a consequence of deletions of the
exon 4 or 5 or nonsense mutations encoding truncated
proteins lacking its C-terminal85,92,99. More than 20 ALS-
linked missense OPTN mutations have been reported.
However, the role of most mutations on disease pro-
gression is still poorly understood. The ALS-linked OPTN
mutations Q398X and E478G lead to failure in myosin VI
binding and Myb 1 (Tom1) targeting, causing inhibition
of autophagosome–lysosome fusion90,100. Another het-
erozygous missense mutation in OPTN (V295F) induces
ALS-like cellular phenotypes, like Golgi fragmentation
and increased ER stress101.
TANK-binding kinase 1 (TBK1)
TBK1 is a ubiquitously expressed protein kinase and
contains a serine/threonine kinase domain, an ubiquitin-
like domain and two coiled-coil domains (CCD1 and
CCD2) that mediate homodimerization102. TBK1 has a
critical role in autophagy by regulating the phosphoryla-
tion of the autophagy receptors OPTN, NDP52/CAL-
COCO2, and p62/SQSTM162,102. Phosphorylation of
OPTN by TBK1 increases its affinity to LC3 and its ubi-
quitin binding62,84. The ALS-associated E696K TBK1
mutant, which is deficient in OPTN binding, fails to be
recruited to damaged mitochondria103, suggesting that
mitophagy by OPTN is mediated by TBK1. In addition,
TBK1 phosphorylates p62/SQSTM1 on a residue essential
for its role in autophagic clearance104. Recent studies have
suggested that TBK1 is also critical for autophagy initia-
tion by regulating syntaxin 17 (Stx17) phosphorylation
and the formation of FIP200-ATG13 pre-autophagosomal
structures105. TBK1 has also been implicated in the
maturation of autophagosomes into autolysosomes104,
probably through regulation of the cytoplasmic levels of
dynein106 that regulates autophagosome transport via
microtubules to lysosomes.
Mutations in TBK1 have been shown to cause ALS,
FTD, and a combination of both (ALS–FTD). From a
number of genetics studies with ALS, ALS–FTD, and
FTD patients, more than 40 mutations have been found in
the TBK1 gene that cause either a frameshift or a pre-
mature stop leading to truncated products102,107. Several
ALS-causing TBK1 mutations induce protein truncation
resulting in loss of the CCD2 domain in TBK1, decreasing
its kinase activity107. Some TBK1 mutations also result in
decreased mRNA and protein levels107, which may
decrease activation of autophagy receptors, resulting in
decreased autophagic substrate clearance, and accumu-
lation of protein aggregates in neurons108.
Vacuolar protein sorting 13D (VPS13D)
VPS13D belongs to the VPS13 family, which in humans
comprises of 4 proteins (VPS13A-D) that appear to be
critical for the non-vesicular transport of lipids between
adjacent organelles109,110. Studies in Drosophila intestinal
cells reveal that VPS13D plays an important role in
mitochondrial fission and mitophagy through its putative
ubiquitin-binding UBA domain111. VPS13D functions
downstream of the recruitment of the fission factor Drp1
to control mitochondrial fission, and upstream of ATG8A
to control mitophagy111. However, little is known about
the specific molecular function of VPS13D.
Several heterozygous mutations in VPS13D have been
identified in families with neurological disorders112,113.
Patient-derived fibroblasts and muscle biopsies show
severe alterations in mitochondrial morphology and
energy production112,113, indicating accumulation of
damaged mitochondria. The disease associated with rare
recessive VPS13D variants is a novel, complex, hyperki-
netic neurological disorder of variable age of onset that
can be associated with developmental delay and pro-
gressive spastic ataxia or paraplegia. Individuals can pre-
sent with motor delays and gait instability, as well as
cognitive impairment. Individuals have also presented
with dysarthria, and eye movement abnormalities. The
disorder progresses to spastic ataxia or generalized dys-
tonia, which can lead to loss of independent
ambulation112,113.
Peroxisomal membrane protein 13 (PEX13)
PEX13 is a transmembrane protein that forms part of
the core of the docking/translocation module in peroxi-
somes and regulates protein import during peroxisome
biogenesis114,115. PEX13 loss-of-function impairs the
clearance of damaged mitochondria and the degradation
of Sindbis virus, without disturbing general autop-
hagy116,117. Although PEX13 seems to be important for
mitophagy and virophagy, the mechanism of PEX13 in
selective autophagy remains elusive.
Mutations in PEX13, lead to Zellweger syndrome (ZS),
associated with impaired neuronal migration, neuronal
positioning, and brain development118. Several mutations
has been described in PEX13, including missense, non-
sense, deletions, and splice site mutations, that lead to
complete or partial impairment in peroxisome func-
tion118–120. As peroxisomes are involved in the bio-
synthesis of phospholipids, oxidation of fatty acids and
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detoxification, patients with ZS accumulate long-chain
fatty acids, pristanic acid, phyntanic acid, plasmalogens,
and C27-bile acid intermediates121,122. Mice lacking
PEX13 exhibit many of the clinical features of ZS patients,
as they lack morphologically intact peroxisomes and have
abnormal mitochondrial distribution and morpholo-
gies117,123. Fibroblasts from PEX13-deficient mice or
patient fibroblasts with PEX13 mutations show increased
levels of mitochondrial superoxide and membrane depo-
larization, suggesting that PEX13 loss-of-function can
cause aberrant mitochondrial dynamics and impaired
mitophagy116,117,124,125. Clinically, ZS patients present
with severe hypotonia, ocular abnormalities, such as cat-
aracts or glaucoma, and often show seizures, renal cysts,
and hepatic dysfunction122,126.
Valosin-containing protein (VCP; also known as
p97 or Cdc48)
VCP is a member of the AAA+ -ATPase family of
chaperone-like proteins and is ubiquitously expressed in
all tissues and throughout the brain127. Through its
interaction with ubiquitinated proteins, VCP regulates
diverse cellular functions, including protein degradation
through the proteasome and autophagy128. VCP is essential
for autophagosome maturation through a yet undefined
mechanism. Cells that lack VCP or that express disease-
associated VCP mutants have an accumulation of imma-
ture autophagic vesicles and fail to degrade autophagic
substrates, whereas patient-derived myoblasts accumulate
aberrant autophagosomes and endo-lysosomes129–131.
Mutations in VCP cause a rare and complex multi-
system degenerative disease that manifests with inclusion
body myopathy, Paget’s disease of bone, and frontotemporal
dementia, as well as ALS132,133. VCP disease-associated
mutations are found throughout the protein sequence, but
mostly reside within the N-terminal and D1/2 domains,
which are regions important for substrate and cofactor
association, as well as VCP ATPase activity, resulting to
either imbalanced cofactor binding or aberrant ATPase
activity, as well as reduced protein expression134.
Ubiquilin 2 (UBQLN2)
UBQLN2 is a chaperone protein that delivers ubiquiti-
nated cargo for proteosomal degradation via its ubiquitin-
associated (UBA) and UBL domains135. However, a role
for UBQLN2 in regulating autophagic flux has now also
emerged. Initial studies showed that UBQLN2 binds LC3
and cells depleted from UBQLN2 have impaired autop-
hagosome degradation136,137. Recent studies in flies
showed that Ubqn/UBQLN is required for Torc1/
mTORC1 activity and lysosomal acidification through its
interaction with v-ATPase and its loss leads to defective
autophagy flux138. Consistent with these data, depletion of
UBQLN1, UBQLN2, and UBQLN4 (UBQLNs) in human
cells also cause reduced mTORC1 activity and impaired
autophagic degradation138.
Mutations of UBQLN2 gene are found in cases of
familial ALS and ALS–FTD135 and the majority reside
within its proline-rich domain that is important for
protein–protein interactions139. Expression of the ALS-
associated UBQLN2 P497H mutation in flies results in
impaired autophagic degradation, due to a failure in
lysosomal acidification138, whereas rat spinal motor neu-
rons expressing the UBQLN2 P497H mutation have
decreased LC3 lipidation140. Interestingly, expression of
the P497H or P506T ALS-associated UBQLN2 mutations
in human neuroblastoma cells leads to a deficiency in
protein degradation through the proteasome system139.
Therefore, further work is needed to elucidate the invol-
vement of UBQLN2 in autophagy and disease.
Spastizin, spatacsin, and tectonin β-propeller
repeat-containing protein 2 (TECPR2)
Spastic gait genes (SPG), identified by genetic studies of
hereditary spastic paraplegia (HSP) patients, regulate
several pathways, including ER function, intracellular
membrane trafficking, mitochondrial regulation, myeli-
nation, lipid metabolism, and autophagy141,142.
Spastizin and spatacsin (encoded by the SPG15 and
SPG11 genes, respectively) physically interact and have
similar subcellular distributions, including endosomes,
lysosomes, and ER143–147. Spastizin and spatacsin play
critical roles in autophagic lysosome reformation (ALR), a
mechanism of lysosomal biogenesis that maintains a pool
of lysosomes able to fuse with autophagosomes after pro-
longed starvation148,149. However, spastizin and spatacsin
are differentially involved in autophagosome–endosome
fusion. Both proteins interact with the AP-5 complex and
the small GTP-binding proteins Rab5A and Rab11, which
regulate endosome trafficking and maturation146,150,
whereas spastizin interacts with the beclin1–UVRAG
complex and regulates autophagosome maturation151,152.
Interestingly, although spastizin mutations impair
autophagosome–endosome fusion, spatacsin loss of func-
tion had no effect, implying that only spastizin acts at the
intersection between endocytosis and autophagy150,153.
Tectonin β-propeller repeat-containing protein 2
(TECPR2) has a C-terminal LIR motif which binds to
LC3/GABARAP proteins and acts as positive regulator of
autophagy154–156. Its association with several trafficking
components, including COPII coat proteins, is required
for the maintenance of functional ER exit site and efficient
ER export in an LC3 binding-depending manner156.
However, the exact functions of TECPR2 are still unclear.
HSPs are rare inherited disorders characterized by age-
dependent neurodegeneration of motor neurons,
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manifesting with weakness of the legs (paraplegia) and
involuntary spasms and muscle stiffness (spasticity).
Spastic paraplegia type 11 (SPG11), type 15 (SPG15), and
type 49 (SPG49) are classified as complex HSPs, because
they involve all four limbs as well as additional features,
including abnormalities of the brain, such as a thin corpus
callosum157. SPG11 and SPG15 are the two most com-
mon types of HSP. The onset of symptoms varies greatly.
However, abnormalities usually become noticeable in
adolescence. So far, more than 100 SPG11 and SPG15
mutations have been described, being either nonsense or
insertions or deletions leading to a frameshift, suggesting
a loss-of-function mechanism. Indeed, mice lacking
spastizin or spatacsin develop symptoms consistent with
spastic paraplegia145,149. The clinical features in SPG11
and SPG15 are often indistinguishable, with distinctive
features of early onset Parkinsonism, cognitive impair-
ment, white matter changes, mild cerebellar ataxia, retinal
abnormalities, and lens opacities157–159. SPG49 is caused
by mutated TECPR2, resulting in a premature stop codon
and expression of truncated, rapidly degraded TECPR2
protein155. SPG49 often begins in childhood, starting with
weak muscle tone, which gradually worsens, causing dif-
ficulty in walking. In addition, affected individuals have
moderate to severe intellectual disability and distinctive
physical features, including short stature and micro-
cephaly. In SPG49 patients, autonomic neurons are
affected, causing abnormalities in involuntary body
functions such as heart rate, digestion, and breathing.
Patients often experience gastroesophageal reflux, which
could lead to life-threatening bacterial lung infections.
Ectopic P granules protein 5 (EPG5)
EPG5 is involved in autophagosome maturation and
fusion to the lysosome160–162. EPG5 interacts with Rab7
on late endosomes, co-localizes with LC3-positive
autophagosomes and the assembled SNARE complex
STX17–SNAP29–VAMP8/VAMP7163, which is essential
for fusion of autophagosomes to lysosomes3. These
observations, together with convincing in vitro data,
suggest that GTP-bound Rab7 recruits EPG5 to late
endosomes, enabling endosome–autophagosome fusion
followed by recruitment and assembly of the
STX17–SNAP29–VAMP8/VAMP7 SNARE complex163.
Consequently, EPG5 functions as a tether to specifically
direct fusion of autophagosomes and endosomes and
subsequent fusion to the lysosome.
EPG5 mutations cause Vici syndrome164–166, a rare,
recessive neurodevelopmental disorder with multisystem
involvement, involving underdeveloped corpus callosum,
cataracts, cardiomyopathy, combined immunodeficiency,
developmental delay, hypopigmentation, and failure to
thrive165. Most of the mutations identified in patients
result in a non-functional EPG5 protein due to truncation,
frameshift, premature stop codons or splicing errors.
Consistent with a role for EPG5 in autophagosome fusion
to the lysosome, studies in patient fibroblasts revealed an
accumulation of LC3 and autophagic substrates due to
impaired autophagic flux164,165. Endocytotic uptake and
degradation was normal in the patient cells, indicating
that lysosomal function is maintained and that the EPG5
mutation affects an earlier step in the autophagosome
maturation process165. Furthermore, genetic variants of
EPG5 have been associated with altered age of onset in
Alzheimer’s disease167, consistent with the importance of
autophagy in protection against neurodegeneration.
Vacuolar protein sorting-associated protein 11
(VPS11)
VPS11 is part of the CORVET–HOPS complex, which
is essential for fusion of endosomes or autophagosomes
with lysosomes168. The C846G missense mutation in
VPS11 causes aberrant ubiquitination, accelerated turn-
over of the protein and impaired protein complex stabi-
lity169. A very rare mutation has been also found (reported
in two siblings) that involves a 9 amino acid deletion in
VPS11 (ΔL387_G395) leading to reduced protein
levels170. The HOPS complex instability (due to loss or
reduced levels of VPS11) is associated with dysfunctional
autophagy–lysosome trafficking169.
Mutations in VPS11 cause genetic leukoencephalo-
pathies (gLEs), a group of heterogeneous disorders with
abnormalities affecting the CNS. Patients affected with
gLEs manifest variable neurologic phenotypes, including
motor impairment, hypotonia, pyramidal dysfunction,
dystonia, and/or dyskinesia, ataxia, seizures, cortical
blindness, optic atrophy, and impaired cognitive devel-
opment171. The neuro-imaging features include severe
hypomyelination with clusters of membranous cyto-
plasmic bodies in dermal unmyelinated nerve axons170,
similar to what it has been seen in classic lysosomal sto-
rage diseases.
Sorting nexin-14 (SNX14)
SNX14 belongs to the PXA–RGS–PX–PXC subfamily,
along with SNX13, SNX19, and SNX25.41 Similar to
SNX13, SNX14 contains a putative double transmem-
brane domain including a short cytoplasmic leader
sequence and an RGS domain (regulator of G protein
signaling)172, implying they share similar functions. Dif-
ferent hypotheses have been formulated about the cellular
localization and function of SNX14. Although SNX14 is
co-expressed with endosomal sorting markers173, it is
localized in lysosomes, but not in endosomal or Golgi
compartments174,175. Moreover, a lipid-binding assay
using the PX domain of SNX14 shows binding to PI(3,5)
P2176, the predominant phosphoinositide associated with
lysosomes. SNX14 also localizes at ER–lipid droplet
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contact sites and it may play a role in fatty acid home-
ostasis, which when perturbed contributes to neurological
disease175,177. Altogether, these findings support the
notion that SNX14 is required for proper lysosomal
function and lipid homeostasis.
Mutations in SNX14 cause autosomal recessive spino-
cerebellar ataxia 20 (SCAR20), a neurodevelopmental dis-
order characterized by severely delayed psychomotor
development with poor or absent speech, absent gait and
cerebellar atrophy. At least 18 different point mutations or
deletions have been described, with most resulting in either
truncation or complete loss of the SNX14 protein175.
Fibroblasts from patients carrying a homozygous splice site
SNX14 mutation show accumulation of vacuoles with fine
nonspecific granular material and electron-dense laminated
inclusions178, suggesting that loss of function of SNX14
leads to lipid degeneration and structures similar to mul-
tilamellar bodies. In addition, SNX14 mutant fibroblasts
show abnormal accumulation of p62/SQSTM1-positive
structures, indicating defective autophagosome degrada-
tion178. Consistent with a role in lysosomal function,
mutant fibroblasts have reduced levels of cathepsin D174,175
and accumulation of cholesterol in lysosomes179.
Concluding remarks
Accumulating evidence indicates that impaired autop-
hagy results in human disease. Here, we have reviewed the
genetic variants found in autophagy related proteins and
their association to neurodegenerative diseases. These
proteins act steps throughout the autophagy itinerary and
their loss-of-function results in diverse neurodegenerative
conditions, ranging from developmental disorders to
motor neuron diseases and dementia-associated condi-
tions. Some of these studies are restricted to individual
small families (not large enough to generate significant
genetic linkage), or small genetic association studies that
do not have genome-wide significance. Also, most of the
disease-associated genetic variants have not been char-
acterized in animal models and the only available func-
tional data are from in vitro studies. Hence, additional
work is required to provide robust genetic support,
although in some cases the functional data are consistent
with disease causality. Further studies towards under-
standing how autophagy can be modulated in normal and
disease conditions and how autophagy perturbation leads
to such a diverse conditions are fundamental to under-
stand how to treat human diseases. Drug discovery efforts
towards the development of pharmacological agents that
will restore normal levels of autophagy in human brains
are also required. This is a challenging task as we cur-
rently have no assay to measure autophagy flux in human
brains.
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